Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06984497
NA

Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD

Sponsor: General Hospital of Shenyang Military Region

View on ClinicalTrials.gov

Summary

Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Stem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used in clinical practice. The efficacy of hepatic artery infusion appears to be greater than that of peripheral vein infusion.

Official title: Efficacy and Safety of Different Transplantation Routes of Human Umbilical Cord-mesenchymal Stem Cells in Patients With End-stage Liver Disease

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2025-09

Completion Date

2027-12

Last Updated

2025-08-24

Healthy Volunteers

No

Interventions

OTHER

Infusion of umbilical cord-mesenchymal stem cells through peripheral veins

Umbilical cord-mesenchymal stem cells injected through peripheral veins

OTHER

Infusion of umbilical cord-mesenchymal stem cells through hepatic artery

Umbilical cord-mesenchymal stem cells injected through hepatic artery

Locations (1)

General Hospital of Northern Theater Command Recruiting

Shenyang, Liaoning, China